Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Interest Coverage 8.88
CFN's Interest Coverage is ranked lower than
60% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.66 vs. CFN: 8.88 )
Ranked among companies with meaningful Interest Coverage only.
CFN' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 8.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
» CFN's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CFN Guru Trades in Q2 2014

Jim Simons 125,000 sh (New)
Louis Moore Bacon 109,695 sh (New)
Larry Robbins 1,909,705 sh (New)
Paul Tudor Jones 361,300 sh (+1875.18%)
Vanguard Health Care Fund 5,661,354 sh (+13.90%)
Diamond Hill Capital 242,594 sh (+13.39%)
Steven Cohen 47,800 sh (unchged)
Ray Dalio Sold Out
Robert Olstein 208,000 sh (-6.31%)
First Pacific Advisors 3,801,500 sh (-16.78%)
Steven Romick 3,580,000 sh (-17.23%)
Joel Greenblatt 4,642 sh (-88.82%)
» More
Q3 2014

CFN Guru Trades in Q3 2014

Joel Greenblatt 817,023 sh (+17500.70%)
Jim Simons 394,500 sh (+215.60%)
Diamond Hill Capital 280,969 sh (+15.82%)
Vanguard Health Care Fund 5,661,354 sh (unchged)
Larry Robbins Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Robert Olstein 195,000 sh (-6.25%)
First Pacific Advisors 3,299,800 sh (-13.20%)
Steven Romick 3,090,000 sh (-13.69%)
Paul Tudor Jones 9,100 sh (-97.48%)
» More
Q4 2014

CFN Guru Trades in Q4 2014

First Eagle Investment 120,000 sh (New)
Caxton Associates 30,087 sh (New)
Mario Gabelli 24,988 sh (New)
Vanguard Health Care Fund 5,661,354 sh (unchged)
Robert Olstein Sold Out
First Pacific Advisors Sold Out
Steven Romick Sold Out
Diamond Hill Capital 279,549 sh (-0.51%)
Paul Tudor Jones 8,300 sh (-8.79%)
Joel Greenblatt 290,264 sh (-64.47%)
Jim Simons 17,800 sh (-95.49%)
» More
Q1 2015

CFN Guru Trades in Q1 2015

Joel Greenblatt Sold Out
Vanguard Health Care Fund Sold Out
Mario Gabelli Sold Out
First Eagle Investment Sold Out
Diamond Hill Capital Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CFN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on CareFusion Corp

Robert Olstein Comments on CareFusion Corp - Mar 27, 2015

Similarly, on October 5, 2014, Becton Dickinson (BDX) announced that it had entered into a definitive agreement to acquire CareFusion (CFN) for $58 per share. The Fund sold its holdings in CareFusion as the price of the company’s stock approached the announced acquisition price representing a substantial premium to the Fund’s average cost for the company’s stock.

From Robert Olstein (Trades, Portfolio)’s The Olstein Strategic Opportunities Fund’s Q4 2014 Letter to Shareholders.

Check out Robert Olstein latest stock trades

Top Ranked Articles about CareFusion Corp

Why You Should Not Be Buying Becton Dickinson Just Yet Becton Dickinson is a great company with a strong management team and solid competitive advantage but not a great investment opportunity yet
Becton Dickinson (NYSE:BDX) is a company with which I have done well in the past. I subsequently sold it but keep tabs on it for the irrational reason of having done well with it before. Read more...

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue(Mil) $4081
EPS $ 2.35
Short Percentage of Float1.62%
52-Week Range $37.76 - 60.40
Shares Outstanding(Mil)204.28

Analyst Estimate

Jun15 Jun16 Jun17
Revenue(Mil) 4,063 4,213 4,411
EPS($) 2.79 2.72 3.07
EPS without NRI($) 2.79 2.72 3.07

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:COV, NYSE:BDX, XPAR:EINV, NAS:ILMN, NYSE:BAX, OCSE:COLO B » details
Traded in other countries:TCF.Germany,
CareFusion Corp a Delaware corporation was incorporated on January 14, 2009. It is a medical technology company. The Company offers a portfolio of products in the areas of medication management, infection prevention, operating room and procedural effectiveness, and respiratory care. Its primary product brands includes: Alaris intravenous (IV) infusion systems, Pyxis and Rowa automated medication dispensing and supply management systems, AVEA, Vela and LTV Series respiratory ventilators, ChloraPrep skin antiseptic products, MedMined data mining surveillance software and analytics, Vital Signs single-use consumables for respiratory care and anesthesiology, and Jaeger and SensorMedics cardiopulmonary diagnostic equipment. The Company operates in two business segments: Medical Systems and Procedural Solutions. In the Medical Systems segment, the Company develops, manufacture and market capital equipment and related supplies for medication management, which includes our infusion and medication dispensing technologies, supply management, as well as respiratory ventilation and diagnostic technologies. In the Procedural Solutions segment, the Company develops, manufacture and market single-use skin antiseptic and other patient-preparation products, specialty IV infusion valves, administration sets and accessories, IV catheters, IV drug preparation products, reusable surgical instruments, non-dedicated ventilator circuits and other disposables used for providing respiratory therapy, as well as single-use consumables for respiratory care and anesthesiology. The Company's competitors includes Baxter International; B. Braun; Fresenius Kabi; Hospira; Omnicell; McKesson; Dräger; MAQUET, 3M; ICU Medical; Becton, Dickinson; Baxter International; B. Braun; Hospira; Smiths Medical; CR Bard; Integra Life Sciences; and Teleflex. The Company's operations are subject to the Federal Food, Drug and Cosmetic Act (FDC Act), as implemented and enforced by the United States Food and Drug Administration (FDA).

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK